ANN ARBOR, Mich., Nov. 13 /PRNewswire/ -- NanoBio Corporation announced
today that it will present new data in four presentations that detail
milestones in its clinical and preclinical development programs in
onychomycosis, acne, herpes labialis and genital herpes during the American
Association of Pharmaceutical Scientists (AAPS) meeting November 16-20,
2008 in Atlanta, GA.
The company's presentation schedule during the conference:
Tuesday, November 18, 1:00 PM - 5:00 PM
-- In-vitro Skin Permeation of Novel Antimicrobial Nanoemulsion
-- Lateral Diffusion of a Novel Antifungal Nanoemulsion In-vitro Human
-- Pharmacokinetics of a Novel Topical Antimicrobial Nanoemulsion
Wednesday, November 19, 1:00 - 5:00 PM
-- Long Term Stability of NB-001: A Novel Antiviral Nanoemulsion
These studies confirm the skin permeation, overall safety and long-term stability of nanoemulsion-based therapies. The data support the continued development of NanoBio treatments for a wide range of skin and mucosal infections, including NanoBio's lead products identified above as well as treatments for tinea capitis (ringworm), molluscum contagiosum (pox virus warts) and other topical fungal, bacterial and viral infections.
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, and a broad platform of mucosal vaccines. NanoBio has demonstrated robust efficacy and safety in randomized, double-blind, placebo-controlled phase 2a and phase 2b studies involving over 800 subjects with recurrent herpes labialis. A large phase 2 trial is nearing completion in onychomycosis and clinical trials are planned for acne and an influenza mucosal vaccine in 2009. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved